Novogen (NASDAQ:KZIA) Now Covered by Analysts at BTIG Research

Analysts at BTIG Research assumed coverage on shares of Novogen (NASDAQ:KZIA) in a research note issued to investors on Wednesday,Benzinga reports. The firm set a “buy” rating and a $34.00 price target on the stock. BTIG Research’s price objective would suggest a potential upside of 141.48% from the company’s previous close.

A number of other equities research analysts also recently weighed in on the company. Laidlaw started coverage on Novogen in a report on Wednesday, April 15th. They issued a “buy” rating and a $25.00 target price on the stock. Lake Street Capital began coverage on Novogen in a research report on Thursday, June 11th. They set a “buy” rating and a $32.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Novogen in a research note on Tuesday, April 21st. Finally, Wall Street Zen cut Novogen from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $25.80.

Novogen Trading Down 2.6%

NASDAQ KZIA opened at $14.08 on Wednesday. The firm’s 50 day simple moving average is $12.96 and its 200 day simple moving average is $9.46. Novogen has a 1 year low of $4.86 and a 1 year high of $17.40.

Novogen (NASDAQ:KZIA) last announced its quarterly earnings data on Saturday, February 14th. The company reported ($1.34) EPS for the quarter. The business had revenue of $4.89 million for the quarter. Analysts anticipate that Novogen will post -0.01 earnings per share for the current year.

Novogen Company Profile

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.